乳腺癌21基因检测成本效果分析的系统综述与批判性评价
该系统综述纳入27项21基因检测(ODX)的成本效果分析,其中15项获行业资助。多数研究未将临床特征纳入模拟模型,且仅5项考虑了ODX对化疗使用的异质性效应,行业资助研究均倾向支持ODX具有成本效果。
要点
- 多数分析因模型设计偏倚可能高估ODX的成本效果。
- 行业资助研究全部报告ODX节约成本,非资助研究结果不同。
- 仅少数研究正确模拟ODX对低危和高危患者化疗使用的双向影响。
核心结论
- 尽管多数已发表分析显示ODX具有成本效果,但其研究设计存在增加偏倚风险的问题。
研究设计与样本
- 系统文献综述纳入27项21基因检测(ODX)的成本效果分析(CEA)。
主要发现
- 27项分析中15项获行业资助;18项未将常用化疗决策的临床特征纳入模拟模型;仅5项假设ODX增加临床低危患者化疗使用而减少临床高危患者化疗使用;无研究使用基于人群的ODX复发评分与肿瘤特征联合分布;12项不当假设低复发评分组化疗会增加远处复发;所有5项报告ODX节约成本的研究均获行业资助;2项报告增量成本效果比>50,000美元/质量调整生命年的研究未获行业资助。
关键数值与推荐
- 报告ODX节约成本的研究均为行业资助;报告增量成本效果比>50,000美元/质量调整生命年的研究未获行业资助。
临床怎么用
- 临床解读ODX成本效果证据时需关注模型设计偏倚及资助来源对结论的影响。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Prior studies examining cost effectiveness of the 21-gene assay (Oncotype DX [ODX]) for women with hormone receptor-positive, early-stage breast cancer have yielded disparate results. We aimed to explore why these analyses may have yielded different conclusions. Methods We conducted a systematic literature review of cost-effectiveness analyses (CEAs) of ODX. We examined the extent to which the structure of CEA modeling, the assumptions of the models, and the selection of input parameters influenced cost-effectiveness estimates. We also explored the prevalence of industry funding and whether industry funding was associated with study designs favoring ODX. Results We identified 27 analyses, 15 of which received industry funding. In 18 studies, the clinical characteristics (eg, tumor size and grade) commonly used to make chemotherapy decisions were not incorporated into simulation modeling; thus, these studies would favor ODX being cost effective and might not reflect clinical practice. Most studies ignored the heterogeneous effect of ODX on chemotherapy use; only five studies assumed that ODX would increase chemotherapy use for clinically low-risk patients but decrease chemotherapy use for clinically high-risk patients. No study used population-based joint distributions of ODX recurrence score and tumor characteristics, and 12 studies inappropriately assumed that chemotherapy would increase distant recurrence for the low recurrence score group; both approaches overestimated the benefits of ODX. Industry-funded studies tended to favor ODX; all five studies that reported ODX as being cost saving were industry funded. In contrast, two studies that reported an incremental cost-effectiveness ratio > $50,000 per quality-adjusted life-year were not funded by industry. Conclusion Although a majority of published analyses indicated that ODX is cost effective, they incorporated study designs that can increase the risk of bias.
引用
- Wang SY, Dang W, Richman I, et al. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. J Clin Oncol. 2018. PMID: 29659329. doi:10.1200/JCO.2017.76.5941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。